Skip to main content

Table 1 Cost inputs per cycle per model health state

From: Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study

  EVE plus EXE BEV plus PACL BEV plus CAPE
Total Pre-progression cost/cycle    
Drug acquisition cost 2,447.75 € 3,806.42 € 3,510.97 €
Administration cost 0 € 260.89 € 115.95 €
Pre-treatment costs 0 € 82.58 € 36.69 €
Lab tests 42.82 € 52.41 € 48.25 €
Monitoring cost 52.34 € 52.34 € 52.34 €
Prophylactic treatment cost - 274.72 € 416.77 €
Total post-progression cost/cycle 1,057.41 € 1,057.41 € 1,057.41 €
End-of-life cost 823.60 € 823.60 € 823.60 €
  1. EVE: everolimus; EXE: exemestane; BEV: bevacizumab; PACL: paclitaxel; CAPE: capecitabine